Puma Biotechnology (PBYI) Operating Leases (2019 - 2026)

Puma Biotechnology (PBYI) has 8 years of Operating Leases data on file, last reported at $4.5 million in Q1 2026.

• Quarterly Operating Leases fell 20.77% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 20.77% YoY) and the FY2025 annual result came in at $4.7 million, up 215.19% from the prior year.
• Operating Leases retreated to $4.5 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $15.0 million in Q1 2022 to a low of $1.5 million in Q4 2024.
• A 5-year average of $8.9 million and a median of $8.3 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases tumbled 78.76% — and 2025, when it soared 215.19%.
• Tracing PBYI's Operating Leases over 5 years: stood at $11.8 million in 2022, then tumbled by 40.56% to $7.0 million in 2023, then plunged by 78.76% to $1.5 million in 2024, then soared by 215.19% to $4.7 million in 2025, then declined by 3.46% to $4.5 million in 2026.
• The last three Operating Leases figures came in at $4.5 million (Q1 2026), $4.7 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.